Morgan Stanley’s Endocyte, Inc. Common Stock ECYT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2018
Q4 | – | Sell |
-327,093
| Closed | -$5.81M | – | 6875 |
|
|
2018
Q3 | $5.81M | Buy |
327,093
+15,097
| +5% | +$259K | ﹤0.01% | 3022 |
|
|
2018
Q2 | $4.3M | Buy |
311,996
+114,077
| +58% | +$1.35M | ﹤0.01% | 3323 |
|
|
2018
Q1 | $1.8M | Buy |
197,919
+31,256
| +19% | +$172K | ﹤0.01% | 4099 |
|
|
2017
Q4 | $714K | Sell |
166,663
-3,913
| -2% | -$18.6K | ﹤0.01% | 4766 |
|
|
2017
Q3 | $241K | Sell |
170,576
-369,409
| -68% | -$515K | ﹤0.01% | 5259 |
|
|
2017
Q2 | $811K | Buy |
539,985
+442,374
| +453% | +$950K | ﹤0.01% | 4515 |
|
|
2017
Q1 | $251K | Sell |
97,611
-125,299
| -56% | -$290K | ﹤0.01% | 5204 |
|
|
2016
Q4 | $568K | Buy |
222,910
+141,586
| +174% | +$407K | ﹤0.01% | 4861 |
|
|
2016
Q3 | $251K | Buy |
81,324
+5,437
| +7% | +$16.9K | ﹤0.01% | 4913 |
|
|
2016
Q2 | $244K | Sell |
75,887
-96,778
| -56% | -$355K | ﹤0.01% | 4840 |
|
|
2016
Q1 | $535K | Sell |
172,665
-46,446
| -21% | -$152K | ﹤0.01% | 4395 |
|
|
2015
Q4 | $878K | Sell |
219,111
-17,501
| -7% | -$80.6K | ﹤0.01% | 4155 |
|
|
2015
Q3 | $1.08M | Buy |
236,612
+107,352
| +83% | +$562K | ﹤0.01% | 4038 |
|
|
2015
Q2 | $671K | Buy |
129,260
+32,145
| +33% | +$193K | ﹤0.01% | 4499 |
|
|
2015
Q1 | $608K | Buy |
97,115
+4,741
| +5% | +$27.4K | ﹤0.01% | 4522 |
|
|
2014
Q4 | $581K | Sell |
92,374
-14,579
| -14% | -$88.9K | ﹤0.01% | 4563 |
|
|
2014
Q3 | $651K | Sell |
106,953
-2,651
| -2% | -$18.1K | ﹤0.01% | 4388 |
|
|
2014
Q2 | $722K | Sell |
109,604
-2,952
| -3% | -$33.3K | ﹤0.01% | 4307 |
|
|
2014
Q1 | $2.68M | Buy |
112,556
+55,976
| +99% | +$812K | ﹤0.01% | 3170 |
|
|
2013
Q4 | $604K | Sell |
56,580
-46,585
| -45% | -$514K | ﹤0.01% | 4306 |
|
|
2013
Q3 | $1.38M | Sell |
103,165
-1,566
| -1% | -$24.8K | ﹤0.01% | 3523 |
|
|
2013
Q2 | $1.38M | Buy |
+104,731
| New | +$1.41M | ﹤0.01% | 3442 |
|
Other funds holding ECYT
Morgan Stanley's ECYT Position: Q4 2018 in Review
Morgan Stanley sold out of Endocyte, Inc. Common Stock (ECYT) in Q4 2018, closing a stake of 327,093 shares — an estimated $5.81M sold.
Morgan Stanley first reported a position in ECYT in Q2 2013 and held it in 22 quarters. The position peaked at $5.81M in Q3 2018. 2 funds tracked by Wall St. Rank hold ECYT as of Q4 2018.
- Morgan Stanley reported no remaining Endocyte, Inc. Common Stock position as of Q4 2018 after selling out during the quarter.
- Morgan Stanley sold 327,093 Endocyte, Inc. Common Stock shares in Q4 2018, an estimated $5.81M.
- Morgan Stanley first reported a position in Endocyte, Inc. Common Stock in Q2 2013 and held it in 22 quarters.
- Morgan Stanley's Endocyte, Inc. Common Stock position peaked at $5.81M in Q3 2018.
- 2 funds tracked by Wall St. Rank held Endocyte, Inc. Common Stock as of Q4 2018.
Based on Morgan Stanley's 13F filing for Q4 2018, filed 14 Feb 2019.